MX2022013977A - Politerapia de cicloserina y pentoxifilina para el tratamiento de la depresion. - Google Patents

Politerapia de cicloserina y pentoxifilina para el tratamiento de la depresion.

Info

Publication number
MX2022013977A
MX2022013977A MX2022013977A MX2022013977A MX2022013977A MX 2022013977 A MX2022013977 A MX 2022013977A MX 2022013977 A MX2022013977 A MX 2022013977A MX 2022013977 A MX2022013977 A MX 2022013977A MX 2022013977 A MX2022013977 A MX 2022013977A
Authority
MX
Mexico
Prior art keywords
cycloserine
depression
treatment
combination therapy
pentoxifylline
Prior art date
Application number
MX2022013977A
Other languages
English (en)
Inventor
Yong Ha Chi
Sukchan Lee
Dong Cheol Jang
Hyeonjoo Hwang
Original Assignee
Neurorive Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurorive Inc filed Critical Neurorive Inc
Publication of MX2022013977A publication Critical patent/MX2022013977A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención proporciona una composición combinada para prevenir o tratar la depresión, que comprende (i) cicloserina o una sal farmacéuticamente aceptable de la misma; y (ii) pentoxifilina o una sal farmacéuticamente aceptable de la misma. La composición combinada puede usarse de manera eficaz como antidepresivo.
MX2022013977A 2020-05-07 2021-05-07 Politerapia de cicloserina y pentoxifilina para el tratamiento de la depresion. MX2022013977A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200054618 2020-05-07
PCT/KR2021/005711 WO2021225397A1 (ko) 2020-05-07 2021-05-07 우울증 치료를 위한 사이클로세린 및 펜톡시필린 병용 요법

Publications (1)

Publication Number Publication Date
MX2022013977A true MX2022013977A (es) 2022-11-30

Family

ID=78468265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013977A MX2022013977A (es) 2020-05-07 2021-05-07 Politerapia de cicloserina y pentoxifilina para el tratamiento de la depresion.

Country Status (10)

Country Link
US (1) US20230165866A1 (es)
EP (1) EP4147695A4 (es)
JP (1) JP2023525259A (es)
KR (1) KR102344593B1 (es)
CN (1) CN115515578A (es)
AU (1) AU2021268501A1 (es)
BR (1) BR112022022629A2 (es)
CA (1) CA3174375A1 (es)
MX (1) MX2022013977A (es)
WO (1) WO2021225397A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972685A (zh) * 2003-12-29 2007-05-30 贾森·麦克德维特 治疗复发性的需要治疗的病症的组合物及方法
CN101309682A (zh) * 2005-10-21 2008-11-19 脑细胞股份有限公司 通过pde抑制调节神经发生
AU2015200415A1 (en) * 2005-12-29 2015-02-19 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, methods and uses
WO2008021210A2 (en) * 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US20080064709A1 (en) * 2006-09-11 2008-03-13 Duke University Methods and compositions for the treatment of vascular depression
WO2009124755A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
WO2010099217A1 (en) * 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2558101A4 (en) * 2010-04-15 2013-09-18 Univ Mcgill TOPICAL PAIN TREATMENTS
MX2016003979A (es) * 2013-10-03 2016-06-15 Millennium Pharm Inc Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.
CN110996948A (zh) * 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症

Also Published As

Publication number Publication date
BR112022022629A2 (pt) 2022-12-13
KR20210136875A (ko) 2021-11-17
EP4147695A1 (en) 2023-03-15
AU2021268501A1 (en) 2022-11-03
CA3174375A1 (en) 2021-11-11
WO2021225397A1 (ko) 2021-11-11
EP4147695A4 (en) 2024-04-24
KR102344593B1 (ko) 2021-12-29
JP2023525259A (ja) 2023-06-15
CN115515578A (zh) 2022-12-23
US20230165866A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
AU2017261286A1 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021011488A (es) Compuestos y usos de estos.
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
ZA202211004B (en) 3clpro-targeting phillyrin, derivative thereof, and use thereof against novel coronavirus
MX2022000811A (es) Inhibidores de enzimas.
CR20210021A (es) Apirasas solubilizadas, métodos y usos
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
MX2021008903A (es) Compuestos y usos de los mismos.
MX2022013977A (es) Politerapia de cicloserina y pentoxifilina para el tratamiento de la depresion.